Davis Gregory D 4

What Happened
Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics (SGMO), had portions of vested restricted stock units (RSUs surrendered to the company to satisfy mandatory tax withholding). On Feb 24, 2026 he surrendered 832 shares (priced at $0.4725/share) for $393; on Feb 25, 2026 he surrendered 5,119 shares (priced at $0.47/share) for $2,406. These are withholding dispositions of vested RSUs and not open-market sales.

Key Details

• Transaction dates & prices: Feb 24, 2026 — 832 shares at $0.4725/share ($393); Feb 25, 2026 — 5,119 shares at $0.47/share ($2,406). Total surrendered: 5,951 shares for $2,799.
• Transaction type: Code F — shares surrendered to issuer for mandatory tax withholding (reported as dispositions).
• Shares owned after transaction: Not specified in the excerpt of the filing.
• Notable footnotes:
  • F1/F3: These dispositions represent mandatory tax withholding on RSU vesting and do not reflect discretionary open-market trades.
  • F2/F4: Describe the underlying RSU grants — include shares from a Feb 24, 2023 RSU grant and a Feb 25, 2025 RSU grant with staggered vesting (quarterly installments and subject to continuous service/possible acceleration).
• Filing timeliness: Reported on Feb 26, 2026 for transactions on Feb 24–25, 2026 — appears timely (Form 4 is generally due within two business days).

Context
This was a routine cashless-withholding event tied to RSU vesting (the company retained shares to cover taxes). Such withholding-based dispositions are administrative and typically do not signal an insider’s change in view about the company’s stock.